Pfizer Manufacturing Deutschland GmbH (manufacturing, packaging, quality control and batch release)

The drug is intended for the treatment of adults with chronic myeloid leukemia (CML) with the presence of the Philadelphia chromosome (Ph+). It is used in both newly diagnosed disease in the chronic phase and in cases where previous therapy has been ineffective or intolerable (in the chronic phase, accelerated phase, or blast crisis).

Dosage form: tablets, film-coated

ATC: L01EA04

The drug is intended for the treatment of adults with chronic myeloid leukemia (CML) with the presence of the Philadelphia chromosome (Ph+). It can be used in both newly diagnosed disease in the chronic phase and in cases of accelerated phase or blast crisis, if previous therapy has been ineffective or intolerable.

Dosage form: tablets, film-coated

ATC: L01EA04